The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations

Br J Cancer. 2005 May 9;92(9):1599-610. doi: 10.1038/sj.bjc.6602550.


Vascular and angiogenic processes provide an important target for novel cancer therapeutics. Dynamic contrast-enhanced magnetic resonance imaging is being used increasingly to noninvasively monitor the action of these therapeutics in early-stage clinical trials. This publication reports the outcome of a workshop that considered the methodology and design of magnetic resonance studies, recommending how this new tool might best be used.

Publication types

  • Guideline
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Clinical Trials as Topic
  • Evaluation Studies as Topic
  • Magnetic Resonance Imaging*
  • Neoplasms / blood supply*
  • Neoplasms / drug therapy*
  • Reproducibility of Results
  • Terminology as Topic


  • Angiogenesis Inhibitors
  • Antineoplastic Agents